Galderma Reported Positive Three-Year NEMLUVIO Results
New long-term clinical trial data shows sustained skin clearance and itch reduction in atopic dermatitis patients.
Updated on Oct. 14, 2026 in Asthma
Live Poll
Would you trust a newly approved medication based on three-year clinical trial results?
Galderma has released three-year clinical trial results for its drug NEMLUVIO, demonstrating significant long-term efficacy in treating patients with atopic dermatitis. The findings from the ARCADIA LTE study highlight sustained improvements in skin health and itch reduction for early responders.
Why it matters
The study provides evidence for the durability of NEMLUVIO as a long-term treatment option for individuals suffering from chronic atopic dermatitis symptoms. By maintaining high efficacy levels over 152 weeks, the results support the potential for sustained disease management in adult and adolescent populations.
In the ARCADIA LTE study of 295 early responders aged 12 and older, 76 percent achieved IGA 0/1 skin status by Week 152. Additionally, 50 percent of these patients reached complete skin clearance, defined as EASI-100, at the same three-year milestone.
The players
Galderma
Galderma is a global dermatology company that specializes in the development and distribution of pharmaceutical and aesthetic skin health solutions.
The details
The analysis indicates that 80 percent of study participants achieved an itch-free or nearly itch-free state by the end of the 152-week monitoring period. Broader interim findings involving 1,903 patients showed up to 91 percent achieving EASI-75, with 92 percent reporting improved quality of life.
Timeline
Initial patient response measurements occurred at Week 16.
Pediatric data for ages 2 to 11 was assessed at Week 52.
Skin clearance measurements were recorded at Week 56.
Prurigo nodularis burden was evaluated at Week 148.
Three-year long-term efficacy was measured at Week 152.
The Big Picture
The ARCADIA LTE study provides a longitudinal framework for assessing chronic disease management efficacy over multi-year periods. This report extends the data previously established by the study, confirming the stability of clinical outcomes in long-term treatment scenarios.
Patients with atopic dermatitis may see more consistent treatment options as these results demonstrate sustained skin and itch relief over three years. The data suggests that long-term therapy with NEMLUVIO can reliably manage severe symptoms without the emergence of new safety signals.
The takeaway
These findings underscore the importance of monitoring long-term treatment efficacy to improve patient quality of life. Consistent follow-ups with healthcare providers remain essential for those utilizing biologics to manage chronic inflammatory skin conditions.
Further reading
For more information on dermatological conditions and their management, visit the Asthma section.
Live Poll
Would you trust a newly approved medication based on three-year clinical trial results?
